Droperidol Carinopharm
Butyrophenone Antiemetic for Prevention of Postoperative Nausea and Vomiting
Quick Facts About Droperidol Carinopharm
Key Takeaways About Droperidol Carinopharm
- Effective PONV prevention: Droperidol is a well-established first-line antiemetic that reduces postoperative nausea by 30–40% and vomiting by 35–45% compared with placebo
- Hospital-only medication: Droperidol Carinopharm is given as an intravenous injection by a healthcare professional – it is not self-administered
- QT prolongation risk: Droperidol can prolong the QT interval on an ECG, which in rare cases may cause serious heart rhythm abnormalities – ECG monitoring is recommended
- Low effective doses: Antiemetic doses (0.625–1.25 mg) are much lower than historical anaesthetic doses, which significantly reduces the risk of side effects
- Not for everyone: Droperidol must not be used in patients with Parkinson's disease, phaeochromocytoma, known QT prolongation, severe depression, or coma
What Is Droperidol Carinopharm and What Is It Used For?
Droperidol Carinopharm is an injectable antiemetic medication that belongs to the butyrophenone class of neuroleptic drugs. It is primarily used to prevent and treat nausea and vomiting that can occur after surgery (postoperative nausea and vomiting, or PONV) and to prevent opioid-induced nausea during patient-controlled analgesia (PCA).
Droperidol was first synthesised in 1961 by Paul Janssen at Janssen Pharmaceutica and has been in clinical use for over six decades. It is a potent dopamine D2 receptor antagonist that exerts its antiemetic effect primarily by blocking dopaminergic neurotransmission in the chemoreceptor trigger zone (CTZ) of the medulla oblongata, the area of the brain responsible for triggering the vomiting reflex. At the low doses used for antiemetic purposes (0.625–1.25 mg), droperidol is highly effective with a favourable side effect profile.
Postoperative nausea and vomiting is one of the most common and distressing complications following surgery under general anaesthesia, affecting approximately 30% of all surgical patients and up to 80% of high-risk patients. PONV can lead to patient distress, delayed hospital discharge, aspiration pneumonia, wound dehiscence, and increased healthcare costs. The European Society of Anaesthesiology (ESA) and the Society for Ambulatory Anesthesia (SAMBA) both recommend droperidol as a first-line agent for PONV prophylaxis, alongside ondansetron and dexamethasone.
In the context of postoperative pain management, opioid analgesics such as morphine are commonly administered through patient-controlled analgesia (PCA) devices, which allow patients to self-administer small doses of pain relief as needed. However, opioids frequently cause nausea and vomiting as a side effect. When droperidol is added to the PCA morphine solution at a concentration of 15–50 micrograms per milligram of morphine, it significantly reduces the incidence of opioid-induced emesis without compromising pain relief. This use is approved only for adults.
Droperidol Carinopharm is approved in the European Economic Area (EEA) and is manufactured by Haupt Pharma Livron in France, with marketing authorisation held by Carinopharm GmbH (Germany). It is available in 1 ml brown glass ampoules, each containing 2.5 mg droperidol. The solution is clear, colourless, and free from visible particles. This medication is exclusively for use in healthcare settings under the supervision of qualified medical professionals.
Droperidol has been included in multiple international PONV guidelines as a recommended first-line prophylactic agent. Despite a US FDA black box warning issued in 2001 regarding QT prolongation at higher doses, extensive subsequent research and meta-analyses have demonstrated that low-dose droperidol (0.625–1.25 mg) carries a very low cardiac risk comparable to ondansetron, and many anaesthesiology societies worldwide continue to recommend it as a safe and effective antiemetic.
What Should You Know Before Receiving Droperidol Carinopharm?
Before receiving droperidol, your doctor will review your medical history, current medications, and any known allergies. Droperidol is contraindicated in patients with known QT prolongation, Parkinson's disease, phaeochromocytoma, coma, severe depression, and certain electrolyte imbalances. A baseline ECG may be performed.
Contraindications
You should not receive Droperidol Carinopharm if any of the following apply to you:
- Allergy to droperidol or to any other ingredient in this medicine (mannitol, tartaric acid, sodium hydroxide, or water for injections)
- Allergy to butyrophenone medications such as haloperidol, triperidal, benperidol, melperone, or domperidone
- Known QT prolongation (an abnormality on the ECG) – either a personal history or a family history of this condition
- Low potassium (hypokalaemia) or low magnesium (hypomagnesaemia) levels in the blood – these electrolyte imbalances increase the risk of dangerous heart rhythm disturbances
- Bradycardia (heart rate below 55 beats per minute) or use of medications that cause bradycardia
- Phaeochromocytoma – a tumour of the adrenal gland that produces excess catecholamines
- Coma – droperidol may further depress the central nervous system
- Parkinson's disease – droperidol blocks dopamine receptors, which can worsen parkinsonian symptoms
- Severe depression – droperidol may exacerbate depressive symptoms
Warnings and Precautions
Tell your doctor or anaesthetist before receiving Droperidol Carinopharm if you have or have had any of the following conditions:
- Epilepsy or seizure disorder – droperidol may lower the seizure threshold in susceptible individuals
- Heart disease or cardiac problems – particularly any history of arrhythmia or heart failure
- Family history of sudden death – this may indicate an inherited cardiac conduction abnormality
- Kidney impairment – particularly if you are on long-term dialysis, as drug clearance may be reduced
- Lung disease or breathing difficulties – droperidol may cause respiratory depression, particularly when combined with opioids
- Persistent vomiting or diarrhoea – these can cause electrolyte disturbances (low potassium and magnesium), which increase the risk of QT prolongation
- Use of insulin – droperidol can affect blood sugar regulation
- Use of potassium-depleting diuretics such as furosemide or bendroflumethiazide – these may lower potassium levels and increase the risk of cardiac arrhythmia
- Use of laxatives or corticosteroids – these can also deplete electrolytes
- Personal or family history of venous thromboembolism (blood clots) – neuroleptic drugs have been associated with an increased risk of blood clot formation
- History of alcohol misuse or recent heavy alcohol consumption – this may increase sensitivity to the sedative effects of droperidol
Your doctor or anaesthetist will conduct appropriate assessments before administering droperidol, which may include a 12-lead electrocardiogram (ECG) to evaluate your heart rhythm and QT interval, as well as blood tests to check your electrolyte levels (potassium and magnesium). Continuous pulse oximetry is recommended during and for at least 30 minutes after administration for patients with identified or suspected risk of ventricular arrhythmia.
Pregnancy and Breastfeeding
If you are pregnant, think you might be pregnant, or are planning to become pregnant, tell your doctor before receiving Droperidol Carinopharm. Your doctor will carefully weigh the benefits of antiemetic treatment against any potential risks to the developing baby. Animal reproductive studies have not demonstrated teratogenic effects, but there are limited data on droperidol use in pregnant women, so it should only be used during pregnancy if clearly necessary as determined by your doctor.
If you are breastfeeding and need to receive Droperidol Carinopharm, it is recommended that you receive only a single dose. Droperidol and its metabolites may pass into breast milk in small quantities. Breastfeeding can be resumed once you have recovered from anaesthesia. If you have concerns, discuss the timing of breastfeeding with your doctor or midwife.
Driving and Operating Machinery
Droperidol has a marked effect on the ability to drive and use machinery. You must not drive or operate machinery for at least 24 hours after receiving Droperidol Carinopharm. The sedative effects can impair reaction times, coordination, and judgement. This restriction also applies after general anaesthesia, which is the typical context in which droperidol is administered. Always follow the discharge advice given by your anaesthetist or surgeon regarding when it is safe to resume driving.
Alcohol
You should avoid consuming alcohol for at least 24 hours before and after receiving Droperidol Carinopharm. Alcohol can potentiate the central nervous system depressant effects of droperidol, including sedation, respiratory depression, and hypotension. Your anaesthetist will typically advise you to avoid alcohol as part of standard pre-operative and post-operative instructions.
Sodium Content
Droperidol Carinopharm contains less than 1 mmol sodium (23 mg) per millilitre. This means it is essentially “sodium-free” and is suitable for patients on a sodium-restricted diet.
How Does Droperidol Carinopharm Interact with Other Drugs?
Droperidol has clinically significant interactions with many medications, particularly those that prolong the QT interval. It must not be combined with antiarrhythmics, certain antibiotics, some antidepressants, antipsychotics, antimalarials, or several other drug classes. It also enhances the effects of sedatives, opioids, and blood pressure-lowering medications.
Because droperidol can prolong the QT interval on the ECG, it must not be used concurrently with any other drugs known to have the same effect. The combination of two or more QT-prolonging agents significantly increases the risk of torsade de pointes, a potentially life-threatening ventricular arrhythmia. Additionally, droperidol can enhance the effects of central nervous system depressants and reduce the effectiveness of dopaminergic medications. Your anaesthetist will carefully review your complete medication list before administering droperidol.
Contraindicated Combinations (Must Not Be Used Together)
| Category | Drugs | Risk |
|---|---|---|
| Antiarrhythmics | Quinidine, disopyramide, procainamide, amiodarone, sotalol | Additive QT prolongation – risk of torsade de pointes and cardiac arrest |
| Antibiotics | Azithromycin, erythromycin, clarithromycin, sparfloxacin | QT prolongation – risk of life-threatening arrhythmias |
| Antihistamines | Astemizole, terfenadine | QT prolongation – risk of ventricular arrhythmias |
| Antidepressants | Amitriptyline, maprotiline, fluoxetine, sertraline, fluvoxamine | QT prolongation – risk of cardiac arrhythmias |
| Antipsychotics | Amisulpride, chlorpromazine, haloperidol, melperone, pimozide, sulpiride, sertindole, tiapride | QT prolongation and additive neuroleptic effects |
| Antimalarials | Quinine, chloroquine, halofantrine | QT prolongation – risk of fatal arrhythmias |
| Other QT-prolonging drugs | Cisapride, pentamidine, tacrolimus, tamoxifen, vincamine, domperidone, methadone | Additive QT prolongation – risk of torsade de pointes |
Other Important Interactions
| Drug / Category | Effect | Recommendation |
|---|---|---|
| Metoclopramide and other neuroleptics | Increased risk of extrapyramidal symptoms (involuntary movement disorders) | Avoid concurrent use |
| Sedatives (barbiturates, benzodiazepines) | Enhanced sedation, respiratory depression, and hypotension | Dose reduction of sedatives may be needed |
| Opioid analgesics (morphine, fentanyl) | Enhanced sedation and respiratory depression | Monitor respiratory function closely; adjust opioid doses |
| Antihypertensives | Enhanced blood pressure-lowering effect – risk of significant hypotension | Monitor blood pressure closely during and after administration |
| Dopamine agonists (L-dopa, bromocriptine, lisuride) | Droperidol opposes the effect of dopamine agonists | Avoid concurrent use – particularly relevant for Parkinson's disease patients |
| Cimetidine, ticlopidine, mibefradil | May increase droperidol blood levels by inhibiting its metabolism | Use with caution; monitor for enhanced droperidol effects |
Droperidol Carinopharm is physically incompatible with barbiturate solutions. These drugs must not be mixed in the same syringe or infusion line. Droperidol may only be mixed with morphine sulfate in 0.9% sodium chloride solution. Mixing with any other drugs or solutions should be avoided to prevent precipitation or loss of efficacy.
What Is the Correct Dosage of Droperidol Carinopharm?
Droperidol Carinopharm is administered by slow intravenous injection. The usual adult dose for PONV prophylaxis is 0.625 mg to 1.25 mg, given approximately 30 minutes before the expected end of surgery. Doses are lower for elderly patients, those with liver or kidney impairment, and children.
Droperidol is always administered by a qualified healthcare professional (doctor, anaesthetist, or nurse) in a hospital or clinical setting. The dose is individualised based on the patient's age, weight, overall health status, concurrent medications, type of anaesthesia, and type of surgical procedure. You will not need to measure or administer this medication yourself.
Adults – PONV Prophylaxis and Treatment
Prevention of Postoperative Nausea and Vomiting
Dose: 0.625 mg to 1.25 mg (0.25 to 0.5 ml)
Route: Slow intravenous injection
Timing: Approximately 30 minutes before the expected end of surgery
Repeat doses: May be given every 6 hours as needed
Adults – PCA (Patient-Controlled Analgesia)
Prevention of Opioid-Induced Nausea During PCA
Dose: 15 to 50 micrograms of droperidol per milligram of morphine
Maximum daily dose: 5 mg of droperidol
Administration: Added to the morphine PCA solution in 0.9% sodium chloride
This indication is approved for adults only. Continuous pulse oximetry should be performed for patients with identified or suspected risk for ventricular arrhythmia.
Elderly Patients (Over 65 Years)
PONV Prophylaxis – Elderly
Dose: 0.625 mg (0.25 ml)
Elderly patients should receive the reduced dose due to potentially increased sensitivity to the cardiovascular and central nervous system effects of droperidol. No specific PCA dosing data are available for elderly patients.
Patients with Kidney or Liver Impairment
PONV Prophylaxis – Renal/Hepatic Impairment
Dose: 0.625 mg (0.25 ml)
Patients with impaired kidney or liver function should receive the reduced dose. Droperidol is extensively metabolised by the liver, and reduced clearance may lead to prolonged drug effects. No specific PCA dosing data are available for these patients.
Children (2–11 Years) and Adolescents (12–18 Years)
PONV Prophylaxis – Paediatric (Second-Line)
Dose: 10 to 50 micrograms per kilogram of body weight
Maximum single dose: 1.25 mg
Route: Slow intravenous injection
Timing: Approximately 30 minutes before the expected end of surgery
Droperidol is used as a second-line antiemetic in the paediatric population. It is not recommended for children under 2 years of age due to insufficient safety data. Droperidol is not indicated for PCA use in children or adolescents.
Overdose
Because droperidol is administered in a controlled clinical setting by healthcare professionals, unintentional overdose is unlikely. However, symptoms of droperidol overdose include excessive sedation, drowsiness, low blood pressure, and extrapyramidal symptoms (involuntary movements, muscle rigidity, excessive salivation). At toxic doses, seizures, QT prolongation, ventricular arrhythmias, and sudden death have been reported in rare cases. There is no specific antidote for droperidol. Treatment is supportive: anticholinergic agents (e.g. biperiden) for extrapyramidal symptoms, intravenous fluids for hypotension, airway management, and continuous cardiac monitoring for at least 24 hours. Factors predisposing to torsade de pointes (hypokalaemia, hypomagnesaemia, bradycardia) must be corrected promptly.
What Are the Side Effects of Droperidol Carinopharm?
The most common side effects of droperidol are dizziness and low blood pressure (hypotension). Uncommon side effects include anxiety, rapid heart rate, and oculogyric crisis (involuntary upward rolling of the eyes). Rare but serious effects include neuroleptic malignant syndrome, QT prolongation, and cardiac arrest.
Like all medicines, Droperidol Carinopharm can cause side effects, although not everybody gets them. The likelihood of side effects is dose-dependent; the low antiemetic doses used today (0.625–1.25 mg) are associated with a significantly lower incidence of adverse effects compared with the higher doses previously used for neuroleptanalgesia. If you experience any concerning symptoms after receiving droperidol, inform your doctor or nurse immediately.
- High body temperature, sweating, excessive salivation, and muscle rigidity (signs of neuroleptic malignant syndrome – a rare but potentially fatal reaction)
- Severe allergic reaction or rapid swelling of the face or throat (angioedema)
- Chest pain, palpitations, or fainting (signs of a possible cardiac arrhythmia)
- Swelling, pain, and redness in one leg (signs of a possible deep vein thrombosis), especially if accompanied by chest pain and breathing difficulties (possible pulmonary embolism)
Common
May affect up to 1 in 10 people
- Dizziness
- Low blood pressure (hypotension)
Uncommon
May affect up to 1 in 100 people
- Anxiety
- Oculogyric crisis (involuntary upward rolling of the eyes)
- Rapid heart rate (tachycardia), e.g. more than 100 beats per minute
- Drowsiness
Rare
May affect up to 1 in 1,000 people
- Confusion
- Agitation
- Irregular heart rhythm (arrhythmia)
- Skin rash
- Neuroleptic malignant syndrome (fever, muscle rigidity, altered consciousness, sweating)
- Severe allergic reaction or angioedema
Very Rare
May affect up to 1 in 10,000 people
- Blood disorders (affecting red blood cells or platelets)
- Mood changes including depression, anxiety, and irritability
- Involuntary muscle movements (dyskinesia)
- Seizures or tremors
- Torsade de pointes (life-threatening irregular heartbeat)
- Prolonged QT interval on ECG
- Cardiac arrest
- Sudden death
Not Known
Frequency cannot be estimated from available data
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH) – leading to water retention and low sodium levels
- Hallucinations
- Epileptic seizures
- Parkinson-like symptoms (rigidity, tremor, slowness of movement)
- Psychomotor hyperactivity (extreme restlessness with muscle cramps and twitching)
- Coma
- Fainting (syncope)
- Breathing difficulties (respiratory depression)
- Blood clots in the veins (venous thromboembolism) – including deep vein thrombosis and pulmonary embolism
If you experience any side effects not listed here, or if any effect becomes severe, inform your doctor, nurse, or pharmacist. Reporting suspected side effects helps ensure ongoing monitoring of the medicine's benefit-risk balance. You can report side effects to your national medicines regulatory authority.
How Should You Store Droperidol Carinopharm?
Droperidol Carinopharm should be stored in its original packaging to protect from light. No special temperature requirements apply. The solution must be used immediately after opening. Only clear solutions free from visible particles should be used.
As a hospital-only medication, storage of Droperidol Carinopharm is managed by healthcare professionals and pharmacy departments. However, it is important to understand the storage requirements to ensure safe and effective use:
- Store in the original packaging to protect the solution from light, as droperidol is photosensitive (the brown glass ampoules provide additional light protection)
- No special temperature requirements – store at room temperature
- Single use only – each ampoule is for one-time use. The solution must be used immediately after opening the ampoule. Any unused solution should be discarded
- Check the expiry date before use – do not use after the date stated on the label and carton (the expiry date refers to the last day of the stated month)
- Visual inspection – the solution should be clear and colourless, free from visible particles. Do not use if the solution appears discoloured, cloudy, or contains particles
When diluted with morphine sulfate in 0.9% sodium chloride solution, chemical stability has been demonstrated for 24 hours at 25°C. However, from a microbiological standpoint, the diluted product should be used immediately unless the opening and dilution process excludes the risk of microbial contamination. If not used immediately, storage times and conditions are the responsibility of the user.
Keep all medicines out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste. Return unused medications to a healthcare facility or pharmacy for safe disposal to protect the environment.
What Does Droperidol Carinopharm Contain?
Each millilitre of Droperidol Carinopharm contains 2.5 mg of the active ingredient droperidol. The solution also contains mannitol, tartaric acid, sodium hydroxide, and water for injections. It is a clear, colourless solution supplied in brown glass ampoules.
Active Ingredient
The active substance is droperidol. Each 1 ml ampoule contains 2.5 mg droperidol. Droperidol is a fluorinated butyrophenone derivative with the chemical formula C22H22FN3O2 and a molecular weight of 379.43 g/mol. It acts primarily as a dopamine D2 receptor antagonist with additional mild alpha-1 adrenergic blocking properties.
Inactive Ingredients (Excipients)
The other ingredients are:
- Mannitol – a sugar alcohol used as a tonicity agent to ensure the solution is isotonic with body fluids
- Tartaric acid – used as a pH adjuster to maintain solution stability
- Sodium hydroxide – used for pH adjustment
- Water for injections – the sterile solvent
Sodium Content
This medicine contains less than 1 mmol sodium (23 mg) per ml, meaning it is essentially “sodium-free”. This is relevant for patients on a sodium-restricted diet.
Packaging and Appearance
Droperidol Carinopharm is a clear, colourless solution for injection, free from visible particles. It is supplied in brown glass ampoules (type I glass), each containing 1 ml of solution. Each carton contains 10 ampoules. The brown glass provides protection from light degradation.
Marketing Authorisation Holder and Manufacturer
The marketing authorisation is held by Carinopharm GmbH (Bahnhofstr. 18, 31008 Elze, Germany). The medicine is manufactured by Haupt Pharma Livron (1 rue comte de Sinard, 26250 Livron sur Drôme, France). Droperidol Carinopharm is approved in the European Economic Area, including Austria, Germany, and Sweden.
How Does Droperidol Work in the Body?
Droperidol works by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain, which is the key area responsible for triggering nausea and vomiting. By preventing dopamine from activating this zone, droperidol suppresses the emetic reflex. It also has mild alpha-1 adrenergic blocking activity.
Nausea and vomiting are complex physiological responses coordinated by the vomiting centre (nucleus tractus solitarius) in the medulla oblongata of the brainstem. This centre receives input from several sources, including the chemoreceptor trigger zone (CTZ), the vestibular system, the gastrointestinal tract (via vagal afferents), and the cerebral cortex. The CTZ lies outside the blood-brain barrier in the area postrema and is particularly sensitive to circulating emetogenic substances, including anaesthetic agents, opioids, and metabolic toxins.
The CTZ is rich in dopamine D2 receptors, which play a central role in mediating the emetic signal. When dopamine binds to these receptors, it activates a signalling cascade that ultimately triggers the vomiting reflex. Droperidol is a highly potent and selective antagonist at D2 receptors, meaning it blocks dopamine from binding and thereby interrupts this emetogenic pathway. This is the primary mechanism by which droperidol prevents and treats postoperative nausea and vomiting.
In addition to its dopamine D2 receptor antagonism, droperidol possesses mild alpha-1 adrenergic blocking properties, which contribute to its secondary pharmacological effects. Alpha-1 blockade causes vasodilation and can lead to a modest reduction in blood pressure (hypotension), which is one of the most common side effects observed clinically. This alpha-blocking activity is much less pronounced at the low antiemetic doses (0.625–1.25 mg) than at the higher doses historically used for neuroleptanalgesia.
Droperidol also has weak activity at serotonin 5-HT2 receptors and GABA receptors, though these effects are not considered clinically significant at standard antiemetic doses. Its effect on cardiac ion channels, specifically the human ether-a-go-go-related gene (hERG) potassium channels, is responsible for the dose-dependent QT prolongation observed on ECG. This effect is the basis for the cardiac monitoring recommendations that accompany droperidol use.
Pharmacokinetic Profile
After intravenous administration, droperidol has a rapid onset of action, with antiemetic effects beginning within 3 to 10 minutes. Peak effect is achieved within approximately 30 minutes. The drug is widely distributed throughout the body, crossing the blood-brain barrier readily due to its high lipophilicity.
Droperidol is extensively metabolised in the liver through oxidative dealkylation, N-dealkylation, and reduction pathways, producing pharmacologically inactive metabolites. Approximately 75% of the administered dose is excreted through the kidneys as metabolites, with about 10% excreted in the faeces. The elimination half-life is approximately 2 to 3 hours, although the clinical duration of antiemetic effect often extends to 12–24 hours, which is attributed to slow dissociation from receptor binding sites in the CTZ.
In elderly patients and those with hepatic or renal impairment, drug clearance may be reduced, leading to prolonged clinical effects. This is the rationale for dose reduction in these populations. In children, droperidol has a similar pharmacokinetic profile to adults when dosed on a per-kilogram basis.
Frequently Asked Questions About Droperidol Carinopharm
Droperidol Carinopharm is used to prevent and treat postoperative nausea and vomiting (PONV) in adults and, as a second-line treatment, in children aged 2 to 18 years. In adults, it is also used to prevent nausea and vomiting caused by opioid analgesics during patient-controlled analgesia (PCA) after surgery. It is given as an intravenous injection by a healthcare professional in a hospital or clinical setting.
At the low antiemetic doses used today (0.625–1.25 mg), droperidol has been extensively studied and is considered safe by major anaesthesiology societies worldwide. While the US FDA issued a black box warning in 2001 regarding QT prolongation at higher doses, subsequent large-scale studies and meta-analyses have shown that the cardiac risk at antiemetic doses is very low and comparable to other commonly used antiemetics like ondansetron. Nevertheless, ECG monitoring is recommended, particularly in patients with risk factors for cardiac arrhythmias.
Yes, droperidol can be used in children aged 2 to 11 years and adolescents aged 12 to 18 years as a second-line treatment for preventing postoperative nausea and vomiting. The dose is calculated based on body weight (10 to 50 micrograms per kilogram) up to a maximum of 1.25 mg. It is not recommended for children under 2 years of age, and it is not approved for PCA use in the paediatric population.
After intravenous injection, droperidol begins to take effect within 3 to 10 minutes, with peak antiemetic activity occurring within approximately 30 minutes. Although the drug's elimination half-life is only 2 to 3 hours, its antiemetic effect can last for 12 to 24 hours because droperidol dissociates slowly from dopamine D2 receptors in the brain's chemoreceptor trigger zone.
Droperidol must not be combined with any medications that prolong the QT interval on the ECG. This includes certain antiarrhythmics (quinidine, amiodarone, sotalol), some antibiotics (erythromycin, clarithromycin, sparfloxacin), certain antidepressants (amitriptyline, fluoxetine), some antipsychotics (haloperidol, pimozide), antimalarials (quinine, chloroquine), and others such as methadone, cisapride, and domperidone. Combining these drugs with droperidol significantly increases the risk of life-threatening cardiac arrhythmias.
No, you must not drive or operate machinery for at least 24 hours after receiving Droperidol Carinopharm. The sedative effects of droperidol can impair reaction times, coordination, and judgement. Since droperidol is typically given in the context of general anaesthesia, the same 24-hour restriction applies for the anaesthetic itself. Always follow the specific discharge advice given by your anaesthetist or surgeon.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 2020;131(2):411–448. doi:10.1213/ANE.0000000000004833
- Schaub I, Lysakowski C, Elia N, Tramèr MR. Low-dose droperidol (≤1 mg or ≤15 μg/kg) for the prevention of postoperative nausea and vomiting in adults: quantitative systematic review of randomised controlled trials. European Journal of Anaesthesiology. 2012;29(6):286–294.
- Apfel CC, Korttila K, Abdalla M, et al. A Factorial Trial of Six Interventions for the Prevention of Postoperative Nausea and Vomiting. New England Journal of Medicine. 2004;350(24):2441–2451.
- Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and/or torsade de pointes during electrophysiologic study? A controlled study. Anesthesiology. 2007;107(4):531–536.
- European Medicines Agency (EMA). Droperidol – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report. Journal of Clinical Anesthesia. 2005;17(1):62–65.
- British National Formulary (BNF). Droperidol. NICE BNF monograph. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in anaesthesiology, clinical pharmacology, and perioperative medicine.
Medical Writers
Board-certified physicians specialising in anaesthesiology and clinical pharmacology with documented academic and clinical experience in perioperative medicine.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ESA, ASA, SAMBA, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.